← Back to Screener
Cytosorbents Corp. (CTSO)
Price$0.65
Favorite Metrics
Price vs S&P 500 (26W)-37.52%
Price vs S&P 500 (4W)-12.43%
Market Capitalization$41.24M
All Metrics
Book Value / Share (Quarterly)$0.09
P/TBV (Annual)15.00x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)2.23%
Cash Flow / Share (Quarterly)$-0.16
Price vs S&P 500 (YTD)-2.98%
Gross Margin (TTM)71.48%
Net Profit Margin (TTM)-22.12%
EPS (TTM)$-0.13
10-Day Avg Trading Volume0.07M
EPS Excl Extra (TTM)$-0.13
Revenue Growth (5Y)-2.00%
EPS (Annual)$-0.13
ROI (Annual)-36.32%
Gross Margin (Annual)71.48%
Net Profit Margin (5Y Avg)-62.45%
Cash / Share (Quarterly)$0.10
Revenue Growth QoQ (YoY)41.56%
ROA (Last FY)-18.56%
Revenue Growth TTM (YoY)4.13%
EBITD / Share (TTM)$-0.22
ROE (5Y Avg)-116.40%
Operating Margin (TTM)-41.30%
Cash Flow / Share (Annual)$-0.28
P/B Ratio6.99x
P/B Ratio (Quarterly)6.80x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.39x
Net Interest Coverage (TTM)-2.98x
ROA (TTM)-17.38%
EPS Incl Extra (Annual)$-0.13
Current Ratio (Annual)2.13x
Quick Ratio (Quarterly)1.42x
3-Month Avg Trading Volume0.10M
52-Week Price Return-37.37%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.04
P/S Ratio (Annual)1.11x
Asset Turnover (Annual)0.84x
52-Week High$1.39
Operating Margin (5Y Avg)-63.98%
EPS Excl Extra (Annual)$-0.13
CapEx CAGR (5Y)-15.13%
Tangible BV CAGR (5Y)-48.65%
26-Week Price Return-30.63%
Quick Ratio (Annual)1.42x
13-Week Price Return-6.64%
Total Debt / Equity (Annual)2.82x
Current Ratio (Quarterly)2.13x
Enterprise Value$51.662
Revenue / Share Growth (5Y)-10.83%
Asset Turnover (TTM)0.79x
Book Value / Share Growth (5Y)-44.79%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)2.64x
Pretax Margin (Annual)-23.20%
Cash / Share (Annual)$0.10
3-Month Return Std Dev61.27%
Gross Margin (5Y Avg)67.33%
Net Income / Employee (TTM)$-0
ROE (Last FY)-138.88%
Net Interest Coverage (Annual)-6.19x
EPS Basic Excl Extra (Annual)$-0.13
Receivables Turnover (TTM)4.99x
Total Debt / Equity (Quarterly)2.82x
EPS Incl Extra (TTM)$-0.13
Receivables Turnover (Annual)4.99x
ROI (TTM)-32.52%
P/S Ratio (TTM)1.11x
Pretax Margin (5Y Avg)-65.04%
Revenue / Share (Annual)$0.60
Tangible BV / Share (Annual)$0.04
Price vs S&P 500 (52W)-72.00%
Year-to-Date Return0.95%
5-Day Price Return9.52%
EPS Normalized (Annual)$-0.13
ROA (5Y Avg)-39.37%
Net Profit Margin (Annual)-22.12%
Month-to-Date Return13.98%
Cash Flow / Share (TTM)$-0.50
EBITD / Share (Annual)$-0.25
Operating Margin (Annual)-41.30%
LT Debt / Equity (Annual)2.82x
ROI (5Y Avg)-68.38%
LT Debt / Equity (Quarterly)2.82x
EPS Basic Excl Extra (TTM)$-0.13
P/TBV (Quarterly)15.00x
P/B Ratio (Annual)6.80x
Inventory Turnover (TTM)2.64x
Pretax Margin (TTM)-23.20%
Book Value / Share (Annual)$0.09
Price vs S&P 500 (13W)-9.02%
Beta1.49x
Revenue / Share (TTM)$0.59
ROE (TTM)-79.88%
52-Week Low$0.50
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Surgical & Medical Instruments(108)
| Symbol | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|
CTSOCytosorbents Corp. | 1.11x | -2.00% | 71.48% | -41.30% | $0.65 |
SYKStryker Corporation | 5.17x | 11.84% | 64.57% | 19.43% | $338.34 |
BSXBoston Scientific Corp. | 4.58x | 15.16% | 69.01% | 18.00% | $60.99 |
MMM3M Company | 3.21x | -4.97% | 39.92% | 18.55% | $151.40 |
MDLNMedline Inc. Class A common stock | 2.20x | — | 26.44% | 7.78% | $48.26 |
BDXBecton, Dickinson and Co. | 2.06x | 6.32% | 46.42% | 12.15% | $158.64 |
RMDResMed Inc. | 6.07x | 11.72% | 60.85% | 33.70% | $226.14 |
DXCMDexCom, Inc. | 5.33x | 19.33% | 62.09% | 19.56% | $64.62 |
WSTWest Pharmaceutical Services, Inc. | 6.29x | 7.44% | 35.91% | 19.03% | $278.00 |
PODDInsulet Corporation | 5.19x | 24.53% | 71.63% | 12.92% | $200.87 |
PENPenumbra, Inc. | 9.24x | 20.16% | 67.14% | 13.48% | $329.71 |
About
CytoSorbents develops proprietary polymer adsorption technology to treat life-threatening conditions in intensive care and cardiac surgery. Its EU-approved flagship product, CytoSorb, functions as an extracorporeal cytokine absorber designed to reduce inflammation and prevent multiple organ failure in critical illnesses such as sepsis and trauma. The company generates revenue from product sales across Germany and the United States, supplemented by government grants, with distribution through direct sales and strategic partnerships.